APA (7th ed.) Citation

Reinisch, W., Sandborn, W. J., Danese, S., Hébuterne, X., Kłopocka, M., Tarabar, D., . . . Vermeire, S. (2021). Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. Journal of Crohn's and colitis, 15(6), 938-949. https://doi.org/10.1093/ecco-jcc/jjab023

Chicago Style (17th ed.) Citation

Reinisch, Walter, et al. "Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II." Journal of Crohn's and Colitis 15, no. 6 (2021): 938-949. https://doi.org/10.1093/ecco-jcc/jjab023.

MLA (9th ed.) Citation

Reinisch, Walter, et al. "Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II." Journal of Crohn's and Colitis, vol. 15, no. 6, 2021, pp. 938-949, https://doi.org/10.1093/ecco-jcc/jjab023.